Scientific letter

Solid Pseudopapillary Tumor of the Pancreas: Case Report and Review of the Literature

Tumor seudopapilar sólido del páncreas: presentación de un caso y revisión del tema

Solid pseudopapillary tumors (SPT), which have been characterized by Hamoudi, represent 1%–2% of all pancreatic tumors. They are frequently incidental findings during ultrasound or computed tomography (CT) studies.

The aim of this article is to present a new clinical case and provide updated information about this pathology.

The patient is a 47-year-old woman, with no personal history of interest, who came to our consultation due to epigastralgia that had been growing progressively in intensity over the previous 2 months. Lab work-up showed no alterations and tumor levels were normal. Abdominal ultrasound detected a pancreatic mass measuring 10 cm × 6 cm.

CT scan showed evidence of a lesion in the head and body of the pancreas measuring 11 cm × 6 cm × 9 cm that was predominantly solid, partially calcified, with heterogeneous density and slight radiotracer uptake, and an irregular, poorly defined outline. The mass was compressing and displacing the splenoportal axis, which was completely surrounded. There was also extensive contact with the bifurcation of the celiac trunk with the common hepatic artery and splenic artery, which it surrounded by 50% (Figs. 1 and 2). Endoscopic ultrasound with cytology determined the mass to be an SPT.

Using subcostal laparotomy, we located the tumor in the head/uncinate process/body of the pancreas (Fig. 3), encompassing the mesenteric-portal axis. Total pancreaticoduodenectomy was performed with splenectomy and lymph node dissection.

---

dissection, without pylorus preservation. Venous reconstruction was done with a cadaveric mesenteric-portal vein Y graft measuring 7 cm. Anastomoses were created to connect the 2 mesenteric vein ends to the Y graft and the other end to the portal vein. Afterwards, transmesocolic hepaticojejunostomy and gastrojejunostomy were performed in the same antecolic loop.

The pathology results (Figs. 4 and 5) reported an epithelial mass that was solid-cystic, pseudoencapsulated and heterogeneous. The neoplastic cells formed pseudopapillary structures with long, fibrotic, vascularized connective axes. There was no atypia and few mitoses. The more solid areas had macrophage foam cell aggregates surrounded by cholesterol crystals and multinucleated giant cells. There were signs of stromal calcification with degenerated areas. No structures with poor prognosis were observed. Ki-67 was
1%–2%. Immunohistochemistry techniques (Fig. 6) defined it as an SPT with reactive lymphadenitis (0/16).

The patient’s later progress was good, but imaging studies demonstrated a thrombosis of the portal axis that did not affect liver function.

The etiology of SPT is unknown. The male:female ratio is 1:9.5, and these tumors usually appear in the 2nd and 3rd decades of life.3,6 Clinical manifestations are abdominal pain (as in our case), palpable mass, dyspepsia, fullness, jaundice, nausea, vomiting and weight loss.2

These tumors may also be incidental findings during complementary studies, such as ultrasound and/or CT done for various reasons.5,7 The most frequent location is the head of the pancreas (39.8%), followed by the tail (24.1%). As in our patient, CT shows less uptake in the center of the cysts and increased uptake in the solid surrounding areas. Calcifications are also characteristic.7

Currently, magnetic resonance imaging (MRI) is better than CT for detecting the solid or cystic components of the tumor,1,5,7,8 as well as cystic degeneration.1 In the series by Guo et al.,8 there were degenerative changes in the 24 cases reported. Although tumor characterization is high in this type of tumors using imaging tests, histology studies with cytology or Tru-Cut biopsy are a great help in differentiating pancreatic pseudopapillary tumors from other tumors, as occurred in our case.

The review by Yu et al.5 recorded 553 cases in 13 years. There was suspicion or diagnosis before surgery in only 77 patients, demonstrating that CT and MRI combined with age and patient gender are sufficient to indicate surgery, while interventional procedures should only be done when there is an uncertain diagnosis and in tumors smaller than 3 cm.5,8,9

Macroscopically, these tumors are yellowy-brown and soft in consistency. On the cut surface, there are solid,
hemorrhagic, necrotic and cystic areas, mainly compromising the tail of the pancreas. 

Immunohistochemistry is positive for: vimentin, α-1-antitrypsin, α-1-antichymotrypsin, neuronal specific enolase, CD10 and progesterone receptors (our case), and close to 75% also express cyclin D1. 

Radical resection is the treatment of choice, even with metastasis or local recurrence. Lymph node dissection is not recommended. 

Prognosis is good, with low local recurrence (<10%), metastasis or local invasion, as these tumors have a low malignant potential. Guo et al. mentioned that 20/22 patients with a mean follow-up of 68 months had no evidence of disease recurrence, which was similar to Slako et al. 

SPT are tumors with a low malignant potential. Their etiology is unknown, although there is a strong relationship with female sex hormones. Diagnosis before surgery continues to be a challenge for physicians. In patients with a solid-cystic encapsulated mass with hemorrhagic degeneration, calcifications and solid lesion uptake, SPT should be included in the differential diagnosis. Currently, MRI is the study of choice for diagnosis. The treatment of choice is radical surgical resection, which provides a 5-year survival rate of 95%.

REFERENCES


Karla Leonher-Ruezga, Susana Lopez-Espinosa, Angel Moya Herraiz, Judith Perez Rojas, Rafael López Andújar

*Unidad de Cirugía Hepatobiliarpancreatológica y Trasplante, Hospital Universitari i Politècnic La Fe, Valencia, Spain
*Cirugía General, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
*Servicio de Anatomía Patológica, Hospital Universitari i Politècnic La Fe, Valencia, Spain

*Corresponding author.
E-mail address: moyang@gmail.com (A. Moya Herraiz).

2173-5077/$ – see front matter © 2013 AEC. Published by Elsevier España, S.L.U. All rights reserved.